In this landmark fifth episode of The Gut Onc Lab, Drs. Nicholas Hornstein and Timothy Brown welcome their first guest, radiation oncologist Dr. Nina Sanford, to discuss one of the most significant shifts in modern oncology: Organ Preservation. Historically, esophageal and gastric cancers have required highly morbid, "life-changing" surgeries. Today, the team explores how we can leverage advanced imaging, radiation, and immunotherapy to potentially spare the organ without sacrificing survival.
Key highlights include:
- Defining Organ Preservation: Why avoiding esophagectomy or gastrectomy is the goal, provided we maintain oncologic outcomes.
- The SANO Trial Deep Dive: A look at the Phase 3 data establishing "Watch and Wait" as a non-inferior strategy for complete responders, and the modeling studies that suggest where surgery might still pull ahead long-term.
- The MSI-High Exception: How medical oncology is leading the way with chemo-free immunotherapy (PD-1 and CTLA-4 doublets) to achieve near-miraculous clinical complete responses in a subset of patients.
- Radiation as a Biological Tool: Dr. Sanford explains why "one-size-fits-all" radiation is a thing of the past.
- The Burden of Surveillance: A realistic look at "Time Toxicity"—the intensive endoscopy, PET, and CT schedules required to safely manage patients who forgo surgery.
- Multidisciplinary Buy-In: Why organ preservation isn't just about biology; it’s about having a surgical team ready for "salvage" and a GI team dedicated to frequent monitoring.
Whether you're curious about the biological "Magic Rays" of radiation or the latest "Infinity" and "NEONIKA" trial results, this episode defines the current frontier of upper GI sparing.
Chapters:
(00:00) Why Organ Preservation Matters
(03:48) Immunotherapy Enters the Chat
(06:45) Key Evidence for Watch and Wait
(09:45) Quality of Life and Long Term Tradeoffs
(13:10) Radiation Dose and Adaptive Future
(17:32) Cross vs FLOT and RT in Gastric
(20:38) MSI High Chemo Free Pathway
(26:48) Surveillance Protocols and Logistics
(28:23) Ideal Candidates and Feasibility
(31:43) Infrastructure for Community Practice
(33:03) Final Takeaways and Wrap Up
You can find us on X: Gut Onc Lab (@TheGutOncLab) / X
